DETECTWISE
LIVE

Serial Number

88891709

Owner

PARSONS CORPORATION

Attorney

Blade Metzer

First Use Date

May 4, 2020

Filing Date

Apr 28, 2020

Add to watchlist:

No watchlists yet
View on USPTO

DETECTWISE Trademark

Serial Number: 88891709 • Registration: 6715043

DETECTWISE is a trademark filed by PARSONS CORPORATION on April 28, 2020. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

PARSONS CORPORATION (158 trademarks)

Centreville, VA 20120

Entity Type: 03

Trademark Details

Filing Date

April 28, 2020

Registration Date

May 3, 2022

First Use Anywhere

May 4, 2020

First Use in Commerce

May 4, 2020

Published for Opposition

February 15, 2022

Goods & Services

Telethermographic testing systems sold as a unit comprised of thermal imaging cameras, infrared cameras, and computer hardware and recorded computer software for purposes of collecting, analyzing, and displaying information to help identify and prevent the spread of infectious diseases; biometric testing systems comprised of biometric scanners; systems comprised of downloadable electronic health assessment application questionnaires that use artificial intelligence analytics, downloadable and recorded computer software and user interfaces for end-users being touchscreens for electrotechnical and electronic devices, downloadable and recorded computer software that automates reporting, and risk analytics, to measure, analyze and detect indicia of, and possible exposure to, infectious diseases and viruses onsite at public facilities, commercial facilities, and private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities

Medical testing to assist in the diagnosis or treatment of infectious diseases, namely biological on-site testing; medical testing for diagnostic and/or reporting purposes; on-site medical testing for diagnostic or treatment purposes relating to infectious diseases, providing on-site medical testing and medical consultation facilities for preventing the spread of infectious diseases; medical analysis services for diagnostic and treatment purposes provided by on-site medical laboratories for infectious diseases; on-site medical testing, namely, temperature testing, blood pressure testing, pulse rate testing and other testing for purposes of identifying and preventing the spread of infectious diseases; providing medical testing facilities utilizing telethermographic testing systems, providing medical testing facilities utilizing biometric testing systems, and testing centers located on-site at public facilities, commercial facilities, private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities for purposes of identifying and preventing the spread of infectious diseases; medical analysis services for diagnostic and treatment purposes provided by medical laboratories located on-site at public facilities, commercial facilities, private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities for purposes of identifying and preventing the spread of infectious diseases; onsite virus testing at a mass scale, being medical testing for diagnostic or treatment purposes; providing on-site virus and infectious disease medical testing facilities with positive and negative ventilation control with filtration systems to avoid patient and worker transmission; providing walk-up and drive-through infectious disease medical testing facilities; providing modular medical testing facilities for infectious diseases for use on site at public facilities, commercial facilities, and private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities; providing in-person health screening services and turn-key health assessment services at public facilities, commercial facilities, private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities for purposes of identifying potential exposure to and carriers of infectious diseases and viruses and to prevent the spread of infectious diseases; providing modular facilities for on-site testing for infectious diseases for medical diagnostic or treatment purposes; providing mobile modular testing facilities for use in performing on-site testing for medical diagnostic or treatment purposes to prevent the spread of infectious diseases; providing modular testing facilities for on-site virus and infectious disease testing for medical diagnostic or treatment purposes with positive and negative ventilation control with filtration systems to avoid patient and worker transmission; providing modular testing facilities for walk-up and drive-through infectious disease testing for medical diagnostic or treatment purposes, evaluation and analysis; providing modular testing facilities for infectious diseases for medical diagnostic or treatment purposes for use on site at public facilities, commercial facilities, and private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities; Providing mobile modular medical laboratory facilities to provide in-person infectious disease screening services for diagnostic purposes, and providing mobile modular sanitary installations with thermal imaging for dispensing antiseptic and antiviral agents for self-decontamination and for issuing personal protective gear, all located on-site at public facilities, commercial facilities, private facilities, transportation facilities, airports, entertainment and sports facilities, work facilities, office buildings, restaurants and food outlets, retail facilities, shopping malls, manufacturing facilities, hospitals, and other government owned, commercial, retail and residential facilities for purposes of identifying and preventing the spread of infectious diseases

Providing medical testing service in the field of infectious disease research and infectious disease classification to help prevent the spread of infectious diseases

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 19, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 19, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 19, 2022 REAP
REGISTERED-PRINCIPAL REGISTER
May 3, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 15, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 26, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 12, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 11, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 10, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 10, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 8, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 8, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 8, 2022 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 16, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 15, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 15, 2021 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 25, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 25, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 25, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 25, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 25, 2021 COAR
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Jun 9, 2021 AAUA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 8, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 8, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jun 8, 2021 CNRT
USE AMENDMENT ACCEPTED
Jun 8, 2021 IUAA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 5, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 5, 2021 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
May 5, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 5, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 5, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 5, 2021 COAR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2021 CRFA
ASSIGNED TO LIE
Apr 30, 2021 ALIE
AMENDMENT TO USE PROCESSING COMPLETE
Jan 16, 2021 AUPC
USE AMENDMENT FILED
Jan 16, 2021 IUAF
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 15, 2021 TROA
TEAS AMENDMENT OF USE RECEIVED
Jan 15, 2021 EAAU
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 11, 2020 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Sep 11, 2020 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 11, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 11, 2020 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 17, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jul 17, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jul 17, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 13, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 11, 2020 NWOS
NEW APPLICATION ENTERED
May 1, 2020 NWAP